NEW YORK, Sept. 27, 2016 /PRNewswire/ -- RDD Pharma, a leader in developing treatments for anorectal disorders, announces that it has been granted patents in the EU, China, and Russia for methods for treating fecal incontinence. The patents are based on the increase in resting pressure via a topical administration of RDD 0315, an alpha-agonist. Patents are also pending in U.S., Japan, Australia, Brazil, Canada, India and Israel.
RDD 0315 is currently being studied in the treatment of fecal incontinence associated with spinal cord injury (SCI). A successful placebo-controlled Phase 2a study was recently completed showing statistical significance and a ~25% reduction in unwanted fecal incontinence episodes in SCI patients. Good tolerability and safety was also observed, with no systemic absorption as indicated by plasma levels of RDD-0315 being below detectable limits.